drugset / Trial / NCT01459562

First in Human Study of an Anti-IFN Gamma Monoclonal Antibody in Healthy Volunteers

NCT01459562

Phase 1 Completed 20 enrolled Swedish Orphan Biovitrum
RandomizedSequentialTriple-blindBasic science

Summary

The purpose of this study is to determine the safety, pharmacodynamic and pharmacokinetic profiles of a novel therapeutic drug when administered to healthy volunteers.

Timeline

Start
2011-09
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Emapalumab Monoclonal antibody Intravenous

Indications

No indication recorded.